Catalent Completes $460M Common Stock Follow-On Offering

Catalent Completes $460M Common Stock Follow-On Offering

  

Fried Frank acted as counsel to Catalent in an all-primary follow-on offering of 11,431,411 shares of common stock, including 1,491,053 shares sold pursuant to the exercise of the underwriters' green shoe option, for an aggregate amount of US$460 million. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer and animal health products.
 
The Fried Frank team was led by corporate partners Daniel J. Bursky and Joshua Thomas Coleman and included corporate associates Danica E. Curavic, Michael K. Piacentini, and Justin Sedor. 

majormatters-detail.inc